Hematologic Oncology

Co-occurring focal 22q11.22 deletions and IKZF1 alterations were associated with inferior outcomes vs IKZF1 alterations alone in pediatric patients with B-cell acute lymphoblastic leukemia.

Aaron Gerds, MD, MS, provides insight on determining low- vs high-risk primary myelofibrosis, the role of molecular status on treatment, and his approach toward symptom burden assessment.

Srdan Verstovsek, MD, PhD, describes the classic signs and symptoms of primary myelofibrosis (PMF), along with goals of therapy.

Susan M. O’Brien, MD always knew medicine was the field for her. Growing up in a house full of bankers and finance-oriented family members couldn’t deter her from her chosen path.

Considerations for the future treatment landscape of relapsed/refractory CLL, in light of emerging practices and clinical trial data.

Experts detail optimal sequencing strategies when patients with relapsed/refractory CLL move on to the next line of therapy.

An in-depth analysis of current therapeutic options in relapsed/refractory chronic lymphocytic leukemia.

The panel of experts highlight promising clinical trials for the treatment of myelodysplastic syndrome.

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

Amy DeZern, MD, MHS leads a discussion surrounding the mechanism of action and clinical trial data on the use of magrolimab and pevonedistat in patients with high-risk myelodysplastic syndrome.

Rami Komrokji, MD and Gail Roboz, MD, discuss treatment considerations and clinical trial data surrounding the use of venetoclax in patients with myelodysplastic syndrome or acute myeloid leukemia.

Drs Madanat and Sekeres discuss specific patient characteristics affecting selection of treatment for MDS.

Yazan Madanat, MD, explores toxicity and adverse events impacting treatment selection for patients with MDS.

Dan Pollyea, MD, MS provides a high-level overview of the role of allogeneic stem cell transplant at first remission based on risk stratification, highlighting how to select patients for transplant.

Courtney DiNardo, MD emphasizes the importance of understanding the risk of tumor lysis syndrome, monitoring for drug-drug interactions, and performing a bone marrow biopsy at the end of cycle 1 when treating AML with venetoclax.

The first-in-class small molecule HIF-PHI inhibitor roxadustat demonstrated promising efficacy with favorable tolerability when used in the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies, meeting the primary end point of the phase 2 WHITNEY trial.

The FDA has granted priority review to a new drug application seeking the approval of asciminib for the treatment of patients with chronic myeloid leukemia.

Fixed-duration treatment with mosunetuzumab elicited encouraging responses with acceptable safety when used in patients with multiply relapsed follicular lymphoma.

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Ibrahim Aldoss, MD, and James K. McCloskey, MD, share thoughts on how to effectively sequence available treatment modalities for acute lymphocytic leukemia in various patient populations.

Drs Aldoss and McKloskey describe treatments that can be used in the salvage setting of acute lymphocytic leukemia, including CAR T-cell therapy.

Key opinion leaders look forward to upcoming improvements in the frontline management of chronic lymphocytic leukemia.

Experts reflect on core decisions inherent in selecting frontline therapy for patients with CLL, specifically regarding the use of BTK inhibitors, BCL2 inhibitors, anti-CD20 agents, and chemoimmunotherapy.

The FDA has granted a priority review designation to a supplemental biologics license application seeking the approval of abatacept for the prevention of moderate to severe acute graft-versus-host disease in patients aged 6 years and older who are receiving unrelated donor hematopoietic stem cell transplantation.

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

The ability to reflect and boldly choose a professional identity should be discussed, encouraged, and nurtured in every individual.

Peter G. Miller, MD, PhD, discusses the characteristics and risks associated with clonal hematopoiesis and risk-stratification efforts for patients with cancer who are at risk of developing therapy-related secondary malignancies from clonal hematopoiesis.

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.